Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

被引：2
|
作者：
Arslan, Shukaib
Zhang, Jianying
Dhakal, Prajwal
Moran, Jenna A.
Naidoo, Nuthana
Story, Jennifer Lombardi
Pullarkat, Vinod A.
Stein, Anthony S.
Marcucci, Guido
Yaghmour, George
Bhatt, Vijaya R.
Fathi, Amir T.
Aldoss, Ibrahim
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142780
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna
    Naidoo, Nuthana
    Lombardi, Jennifer
    Pullarkat, Vinod
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (03) : E59 - E63
  • [2] Venetoclax combined with hypomethylating agents for favorable risk acute myeloid leukemia: A single center experience
    Bajwa, Shammas
    Parkin, Brian
    Gayle, Arlene A.
    Patel, Rushang D.
    Mori, Shahram
    Pancari, Philip
    Socola, Francisco Andres
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [4] Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
    Saliba, Antoine N.
    John, August J.
    Kaufmann, Scott H.
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 125 - 142
  • [5] Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia
    Kennedy, Vanessa E.
    Hui, Gavin
    Azenkot, Tali
    Gaut, Daria
    Wieduwilt, Matthew J.
    Oliai, Caspian
    Jonas, Brian A.
    Mittal, Varun
    Logan, Aaron C.
    Muffly, Lori S.
    Mannis, Gabriel N.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : E191 - E194
  • [6] Clinical and biological features of favorable-risk acute myelogenous leukemia – is favorable-risk AML really favorable?
    G J Schiller
    Leukemia, 2005, 19 : 326 - 328
  • [7] Clinical and biological features of favorable-risk acute myelogenous leukemia - is favorable-risk AML really favorable?
    Schiller, GJ
    LEUKEMIA, 2005, 19 (03) : 326 - 328
  • [8] Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
    Lachowiez, Curtis A.
    Loghavi, Sanam
    Furudate, Ken
    Montalban-Bravo, Guillermo
    Maiti, Abhishek
    Kadia, Tapan
    Daver, Naval
    Borthakur, Gautam
    Pemmaraju, Naveen
    Sasaki, Koji
    Alvarado, Yesid
    Yilmaz, Musa
    Short, Nicholas J.
    Chien, Kelly
    Ohanian, Maro
    Pierce, Sherry
    Patel, Keyur P.
    Jabbour, Elias
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Takahashi, Koichi
    Konopleva, Marina Y.
    DiNardo, Courtney D.
    BLOOD ADVANCES, 2021, 5 (08) : 2173 - 2183
  • [9] Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
    Johnson, Isla M.
    Bezerra, Evandro D.
    Farrukh, Faiqa
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun Vinod
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD ADVANCES, 2022, 6 (17) : 5227 - 5231
  • [10] Survival outcomes of patients with relapsed or refractory acute myeloid leukemia after venetoclax combined with hypomethylating agents.
    Zainaldin, Carl
    Arora, Sankalp
    Bathini, Sri
    Pandya, Vishruti
    Bae, Sejong
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly Nicole
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna E.
    Di Stasi, Antonio
    Vachhani, Pankit
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18808 - E18808
12345